论文部分内容阅读
为观察膦甲酸钠抗乙型肝炎病毒 (HBV)的近期疗效 ,将 6 7例慢性乙型肝炎患者随机分为 2组 :治疗组 4 7例 ,在常规保肝治疗的基础上加用膦甲酸钠 ;对照组 2 0例 ,仅用常规保肝药物治疗。治疗前后观察患者肝功能、血清HBVDNA含量、乙肝病毒免疫学标志等的变化。结果显示 ,治疗 2周后 ,治疗组肝功能均有恢复 ;4 7例患者中 4 2例HBVDNA水平下降 ,以第 1周明显 ,第 2周时 10例反跳 ;13例HBVDNA转阴 ,其中 5例在用药 1周后即转阴。30例HBeAg阳性患者中 ,2例出现血清转换 ,1例转为弱阳性。提示膦甲酸钠具有明显和快速的抑制乙肝病毒复制、降低病毒量的作用 ,可作为抗病毒序贯疗法的首程用药或联合用药的选择之一。
To observe the short-term curative effect of foscarnet against hepatitis B virus (HBV), 67 patients with chronic hepatitis B were randomly divided into two groups: 47 in the treatment group, with the addition of foscarnet on the basis of conventional hepatoprotective therapy; Control group 20 patients, only conventional hepatoprotective drugs. Before and after treatment, the changes of liver function, serum HBVDNA content, hepatitis B virus immunological markers and so on were observed. The results showed that after 2 weeks of treatment, the liver function of the treatment group recovered. In 42 of 47 cases, the level of HBVDNA decreased in 42 cases, which was obvious in the first week and rebounded in 10 cases in the second week. The HBVDNA was negative in 13 cases 5 cases turned negative after 1 week of treatment. Of 30 HBeAg-positive patients, seroconversion occurred in 2 patients and weakly positive in 1 patient. It is suggested that foscarnet has a significant and rapid inhibitory effect on HBV replication and viral load reduction and may be used as a first-line or combination of anti-viral sequential therapy.